Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 72
Filter
1.
Am J Physiol Endocrinol Metab ; 320(2): E208-E218, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33196297

ABSTRACT

We found that direct free fatty acid (FFA) storage (fatty acid cycling back into adipose tissue) in leg vs. abdominal subcutaneous fat is related to regional differences in adipose tissue diacylglycerol acyltransferase (DGAT) activity under high-FFA conditions and to differences in adipose tissue acyl-CoA synthetase (ACS)activity under meal ingestion conditions. We also found that direct FFA storage rates in leg fat were significantly less in physically active than sedentary adults. Direct FFA storage into adipocytes relates to body fat distribution. Adipose tissue CD36, ACS, and DGAT may account for some of the between-depot and interindividual variability in FFA storage. These studies were to test whether CD36, ACS, or DGAT might be important for direct palmitate storage under meal ingestion or high-FFA conditions. We measured upper (UBSQ) and lower body subcutaneous (LBSQ) adipose tissue FFA storage rates by infusing palmitate tracers intravenously and performing adipose biopsies under hypoinsulinemic (high-FFA) and mixed-meal conditions. We recruited five postmenopausal women, physically active males (5) and females (5), and sedentary males (5) and females (5). We found that 1) the ratio of UBSQ to LBSQ DGAT activity predicted the ratio of palmitate storage [adjusted R = 0.25, F = 8.0, P = 0.01, 95% CI (0.07, 0.48)] under high-FFA conditions; 2) the ratio of UBSQ to LBSQ ACS activity predicted the ratio of palmitate storage under meal conditions [adjusted R = 0.18, F = 6.3, P = 0.02, 95% CI (0.12, 1.28)]; 3) LBSQ direct palmitate storage rates were significantly less in physically active than sedentary and 4) adipose tissue CD36 protein content, ACS, or DGAT activities did not independently predict palmitate storage rates. We conclude that physically active adults have lesser fatty acid cycling back into adipose tissue and that adipose ACS and DGAT may affect competition between UBSQ and LBSQ adipose for direct palmitate storage.


Subject(s)
Diet, High-Fat , Eating/physiology , Fatty Acids, Nonesterified/pharmacokinetics , Palmitic Acid/pharmacokinetics , Subcutaneous Fat/metabolism , Adolescent , Adult , Biopsy , Female , Humans , Lipid Metabolism , Male , Meals , Middle Aged , Subcutaneous Fat/pathology , Young Adult
2.
Int J Mol Sci ; 21(21)2020 Nov 08.
Article in English | MEDLINE | ID: mdl-33171690

ABSTRACT

Pyrroloquinoline quinone (PQQ) is a novel stimulator of mitochondrial biogenesis and cellular energy metabolism. This is the first study investigating regulatory mechanisms and metabolic responses underlying PQQ's action in palmitate-exposed L6 myotubes. Particularly, we assessed alterations in lipid content and composition, expression of metabolic enzymes, and changes in glucose transport. The experiments were conducted using muscle cells subjected to short (2 h) and prolonged (24 h) incubation with PQQ in a sequence of pre- and post-palmitic acid (PA) exposure. We demonstrated the opposite effects of 2 and 24 h treatments with PQQ on lipid content, i.e., a decline in the level of free fatty acids and triacylglycerols in response to short-time PQQ incubation as compared to increases in diacylglycerol and triacylglycerol levels observed after 24 h. We did not demonstrate a significant impact of PQQ on fatty acid transport. The analysis of metabolic enzyme expression showed that the vast majority of PQQ-dependent alterations cumulated in the PA/PQQ 24 h group, including elevated protein amount of peroxisome proliferator activated receptor γ co-activator 1α (PGC-1α), sirtuin-1 (SIRT1), phosphorylated 5'AMP-activated protein kinase (pAMPK), carnitine palmitoyltransferase I (CPT1), citrate synthase (CS), fatty acid synthase (FAS), and serine palmitoyltransferase, long chain base subunit 1 (SPT1). In conclusion, the results mentioned above indicate PQQ-dependent activation of both fatty acid oxidation and lipid synthesis in order to adapt cells to palmitic acid-rich medium, although PQQ did not attenuate insulin resistance in muscle cells.


Subject(s)
Lipid Metabolism/drug effects , Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/metabolism , PQQ Cofactor/pharmacology , Palmitic Acid/pharmacology , Animals , Biological Transport, Active/drug effects , Cell Line , Diglycerides/metabolism , Fatty Acid Transport Proteins/genetics , Fatty Acid Transport Proteins/metabolism , Fatty Acids, Nonesterified/metabolism , Insulin Resistance , PQQ Cofactor/administration & dosage , Palmitic Acid/administration & dosage , Palmitic Acid/pharmacokinetics , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Rats , Sphingolipids/metabolism , Triglycerides/metabolism
3.
Am J Respir Cell Mol Biol ; 61(6): 737-746, 2019 12.
Article in English | MEDLINE | ID: mdl-31461627

ABSTRACT

The impact of lipotoxicity on the development of lung fibrosis is unclear. Saturated fatty acids, such as palmitic acid (PA), activate endoplasmic reticulum (ER) stress, a cellular stress response associated with the development of idiopathic pulmonary fibrosis (IPF). We tested the hypothesis that PA increases susceptibility to lung epithelial cell death and experimental fibrosis by modulating ER stress. Total liquid chromatography and mass spectrometry were used to measure fatty acid content in IPF lungs. Wild-type mice were fed a high-fat diet (HFD) rich in PA or a standard diet and subjected to bleomycin-induced lung injury. Lung fibrosis was determined by hydroxyproline content. Mouse lung epithelial cells were treated with PA. ER stress and cell death were assessed by Western blotting, TUNEL staining, and cell viability assays. IPF lungs had a higher level of PA compared with controls. Bleomycin-exposed mice fed an HFD had significantly increased pulmonary fibrosis associated with increased cell death and ER stress compared with those fed a standard diet. PA increased apoptosis and activation of the unfolded protein response in lung epithelial cells. This was attenuated by genetic deletion and chemical inhibition of CD36, a fatty acid transporter. In conclusion, consumption of an HFD rich in saturated fat increases susceptibility to lung fibrosis and ER stress, and PA mediates lung epithelial cell death and ER stress via CD36. These findings demonstrate that lipotoxicity may have a significant impact on the development of lung injury and fibrosis by enhancing pro-death ER stress pathways.


Subject(s)
Diet, High-Fat/adverse effects , Endoplasmic Reticulum Stress/drug effects , Palmitic Acid/toxicity , Pulmonary Fibrosis/chemically induced , Animals , Apoptosis/drug effects , CD36 Antigens/deficiency , CD36 Antigens/physiology , Epithelial Cells/drug effects , Lung/metabolism , Lung/pathology , Male , Mice , Mice, Inbred C57BL , Palmitic Acid/administration & dosage , Palmitic Acid/pharmacokinetics , Pulmonary Fibrosis/metabolism , Pulmonary Fibrosis/pathology
4.
Am J Physiol Endocrinol Metab ; 317(2): E194-E199, 2019 08 01.
Article in English | MEDLINE | ID: mdl-31013145

ABSTRACT

Positron emission tomography (PET) radiopharmaceuticals can noninvasively measure free fatty acid (FFA) uptake into adipose tissue. We studied 29 volunteers to test whether abdominal and femoral subcutaneous adipose tissue FFA uptake measured using [1-11C]palmitate PET agrees with FFA storage rates measured using an intravenous bolus of [1-14C]palmitate and adipose biopsies. The dynamic left ventricular cavity PET images combined with blood sample radioactivity corrected for the 11CO2 content were used to create the blood time activity curve (TAC), and the constant (Ki) was determined using Patlak analysis of the TACs generated for regions of interest in abdominal subcutaneous fat. These data were used to calculate palmitate uptake rates in abdominal subcutaneous adipose tissue (µmol·kg-1·min-1). Immediately after the dynamic imaging, a static image of the thigh was taken to measure the standardized uptake value (SUV) in thigh adipose tissue, which was scaled to each participant's abdominal adipose tissue SUV to calculate thigh adipose palmitate uptake rates. Abdominal adipose palmitate uptake using PET [1-11C]palmitate was correlated with, but significantly (P < 0.001) greater than, FFA storage measured using [1-14C]palmitate and adipose biopsy. Thigh adipose palmitate measured using PET calculation was positively correlated (R2 = 0.44, P < 0.0001) with and not different from the biopsy approach. The relative differences between PET measured abdominal subcutaneous adipose tissue palmitate uptake and biopsy-measured palmitate storage were positively correlated (P = 0.03) with abdominal subcutaneous fat. We conclude that abdominal adipose tissue FFA uptake measured using PET does not equate to adipose FFA storage measured using biopsy techniques.


Subject(s)
Adipose Tissue/pathology , Fatty Acids, Nonesterified/pharmacokinetics , Positron-Emission Tomography , Subcutaneous Fat/diagnostic imaging , Subcutaneous Fat/metabolism , Adipose Tissue/diagnostic imaging , Adiposity/physiology , Adult , Biopsy , Body Fat Distribution/methods , Body Mass Index , Carbon Isotopes/analysis , Carbon Isotopes/pharmacokinetics , Carbon Radioisotopes/analysis , Carbon Radioisotopes/pharmacokinetics , Female , Humans , Ideal Body Weight/physiology , Lipolysis/physiology , Male , Obesity/metabolism , Obesity/pathology , Overweight/metabolism , Overweight/pathology , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Positron-Emission Tomography/methods
5.
Molecules ; 24(6)2019 Mar 21.
Article in English | MEDLINE | ID: mdl-30901967

ABSTRACT

Enfuvirtide (T20) is the first U.S. FDA-approved HIV fusion inhibitor-based anti-HIV drug. Its clinical application is limited because of its low potency and short half-life. We previously reported that peptide HP23-E6-IDL, containing both N- and C-terminal anchor-tails, exhibited stronger potency and a better resistance profile than T20. Here we designed an analogous peptide, YIK, by introducing a mutation, T639I, and then a lipopeptide, YIK-C16, by adding palmitic acid (C16) at the C-terminus of YIK. We found that YIK-C16 was 4.4- and 3.6-fold more potent than HP23-E6-IDL and YIK against HIV-1IIIB infection and 13.3- and 10.5-fold more effective than HP23-E6-IDL and YIK against HIV-1Bal infection, respectively. Consistently, the ex vivo anti-HIV-1IIIB activity, as determined by the highest dilution-fold of the serum causing 50% inhibition of HIV-1 infection, of YIK-C16 in the sera of pretreated mice was remarkably higher than that of YIK or HP23-E6-IDL. The serum half-life (t1/2 = 5.9 h) of YIK-C16 was also significantly longer than that of YIK (t1/2 = 1.3 h) and HP23-E6-IDL (t1/2 = 1.0 h). These results suggest that the lipopeptide YIK-C16 shows promise for further development as a new anti-HIV drug with improved anti-HIV-1 activity and a prolonged half-life.


Subject(s)
HIV Fusion Inhibitors/pharmacology , HIV-1/drug effects , Palmitic Acid/pharmacology , Peptides/pharmacology , Virus Internalization/drug effects , Amino Acid Sequence , Animals , Circular Dichroism , Disease Models, Animal , Dose-Response Relationship, Drug , HIV Envelope Protein gp41/metabolism , HIV Fusion Inhibitors/chemistry , HIV Infections/drug therapy , HIV Infections/virology , Humans , Mice , Microbial Sensitivity Tests , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Peptides/chemistry , Peptides/pharmacokinetics
6.
Am J Clin Nutr ; 108(6): 1220-1228, 2018 12 01.
Article in English | MEDLINE | ID: mdl-30358799

ABSTRACT

Background: Branched-chain amino acids (BCAAs) are elevated in the insulin-resistant (IR) state. The reasons for this increase remain unclear, but it may be related to abnormalities in BCAA metabolism and free fatty acid (FFA) metabolism. Objective: In this study, we quantified BCAA and FFA kinetics of IR and insulin-sensitive (IS) nonobese Asian men with the use of stable-isotope tracers. We hypothesized that in addition to greater substrate flux, the BCAA oxidative pathway is also impaired to account for the higher plasma BCAA concentration in the IR state. Design: We recruited 12 IR and 14 IS nonobese and healthy Asian men. Oral-glucose-tolerance tests (OGTTs) were performed to quantify insulin sensitivity, and subjects underwent 2 stable-isotope infusion studies. [U-13C6]Leucine was infused to measure leucine flux and oxidation as indexes of BCAA metabolism, whereas [U-13C16]palmitate was infused to measure palmitate flux and oxidation to represent FFA metabolism, The 2H2O dilution method was used to estimate body composition. Results: IR subjects had greater adiposity and significantly higher fasting and post-OGTT glucose and insulin concentrations compared with the IS group. However, none of the subjects were diabetic. Despite similar dietary protein intake, IR subjects had a significantly higher plasma BCAA concentration and greater leucine flux. Leucine oxidation was also greater in the IR group, but the relation between leucine oxidation and flux was significantly weaker in the IR group than in the IS group (r = 0.530 compared with 0.695, P < 0.0388 for differences between slope). FFA oxidation was, however, unaffected despite higher FFA flux in the IR group. Conclusion: The higher plasma BCAA concentration in healthy nonobese individuals with IR is associated with a weaker relation between BCAA oxidation and BCAA flux and this occurs in the presence of accelerated FFA flux and oxidation.


Subject(s)
Amino Acids, Branched-Chain/blood , Amino Acids, Branched-Chain/pharmacokinetics , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/pharmacokinetics , Insulin Resistance/physiology , Adult , Asian People , Blood Glucose/analysis , Carbon Isotopes , Glucose Tolerance Test , Humans , Insulin/blood , Leucine/pharmacokinetics , Male , Oxidation-Reduction , Palmitic Acid/pharmacokinetics
7.
J Cell Biochem ; 119(12): 9752-9763, 2018 12.
Article in English | MEDLINE | ID: mdl-30129212

ABSTRACT

The formation of atherosclerotic changes leads to dysfunction in numerous cell types, especially endothelial cells. In the current experiment, we aimed to show the therapeutic effect of Docosahexaenoic acid on palmitic-induced atherosclerotic changes in the human endothelial lineage. Human Umbilical Vein Endothelial cells were incubated with 1 mM palmitic acid for 48 hours and then exposed to 40 µM docosahexaenoic acid for next 24 hours. Cellular atherosclerosis and lipid removal were confirmed by the application of Oil red O solution. The cell survival rate was studied by using MTT assay and flow cytometry analysis of Annexin V. We also measured the protein level of tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor by immunofluorescence imaging. The transcription level of genes participating in the atherosclerosis signaling pathway was monitored in atherosclerotic endothelial cells before and after treatment with docosahexaenoic acid. The viability of the cells was reduced after 48 hours incubation with palmitic acid. It is noteworthy that the number of viable endothelial cells was increased after exposure to docosahexaenoic acid. Compared with the cells that received palmitic acid, Oil red O staining showed a decrease in the cellular content of fatty acid after incubation with docosahexaenoic acid (P < 0.05). PCR array indicated that the modulation of key genes played a role in atherosclerosis and reached near-control levels. These data support the notion that incubation of atherosclerotic human endothelial cells with docosahexaenoic acid could return the detrimental effects of palmitic acid by modulation of the atherosclerosis signaling pathway.


Subject(s)
Atherosclerosis/genetics , Docosahexaenoic Acids/pharmacology , Palmitic Acid/adverse effects , Apoptosis/drug effects , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cell Survival/drug effects , Gene Expression Regulation/drug effects , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Human Umbilical Vein Endothelial Cells , Humans , Palmitic Acid/pharmacokinetics , Polymerase Chain Reaction , Signal Transduction/genetics , Tumor Necrosis Factor-alpha/metabolism
8.
Am J Physiol Endocrinol Metab ; 310(5): E367-77, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26714850

ABSTRACT

To investigate the biodisponibility of placental transfer of fatty acids, rats pregnant for 20 days were given tracer amounts of [(14)C]palmitic (PA), oleic (OA), linoleic (LA), α-linolenic (LNA), or docosahexaenoic acid (DHA) orally and euthanized at 0.5, 1.0, 2.0, or 8.0 h thereafter. Maternal plasma radioactivity in lipids initially increased only to decline at later times. Most of the label appeared first as triacylglycerols (TAG); later, the proportion in phospholipids (PhL) increased. The percentage of label in placental lipids was also always highest shortly after administration and declined later; again, PhL increased with time. Fetal plasma radioactivity increased with time, with its highest value at 8.0 h after DHA or LNA administration. DHA initially appeared primarily in the nonesterified fatty acids (NEFA) and PA, OA, LA, and LNA as TAG followed by NEFA; in all cases, there was an increase in PhL at later times. Measurement of fatty acid concentrations allowed calculation of specific (radio)activities, and the ratio (fetal/maternal) of these in the plasmas gave an index of placental transfer activity, which was LNA > LA > DHA = OA > PA. It is proposed that a considerable proportion of most fatty acids transferred through the placenta are released into the fetal circulation in the form of TAG.


Subject(s)
Docosahexaenoic Acids/pharmacokinetics , Fetus/metabolism , Linoleic Acid/pharmacokinetics , Oleic Acid/pharmacokinetics , Palmitic Acid/pharmacokinetics , Phospholipids/metabolism , Placenta/metabolism , Triglycerides/metabolism , alpha-Linolenic Acid/pharmacokinetics , Animals , Carbon Radioisotopes , Docosahexaenoic Acids/metabolism , Fatty Acids/metabolism , Fatty Acids/pharmacokinetics , Female , Linoleic Acid/metabolism , Oleic Acid/metabolism , Palmitic Acid/metabolism , Pregnancy , Rats , alpha-Linolenic Acid/metabolism
9.
Pharm Dev Technol ; 21(1): 3-7, 2016.
Article in English | MEDLINE | ID: mdl-25697744

ABSTRACT

BACKGROUND: The initial burst release is a major obstacle to the development of microsphere-formulated drug products. PURPOSE: To investigate the influence of palmitic acid on the characteristics and release profiles of rotigotine-loaded poly(d,l-lactide-co-glycolide) microspheres. MATERIALS AND METHODS: Rotigotine-loaded microspheres (RMS) were prepared using the oil-in-water emulsion solvent evaporation technique. The in vitro characteristics of the RMS were evaluated with scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and a particle size analyzer. The in vitro drug release and in vivo pharmacokinetics of the RMS were investigated. RESULTS AND DISCUSSION: The SEM results showed that the addition of palmitic acid changed the surface morphology of the microspheres from smooth to dimpled and then to non-smooth as the palmitic acid content increased. DSC revealed the existence of molecularly dispersed forms of palmitic acid in the microspheres. The in vitro and in vivo release profiles indicated that the addition of 5% and 8% palmitic acid significantly decreased the burst release of rotigotine from the microspheres, and the late-stage release was delayed as the palmitic acid content increased across the investigated range (5-15%). CONCLUSION: The addition of palmitic acid to the microspheres significantly affects the release profile of rotigotine from RMS.


Subject(s)
Microspheres , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Tetrahydronaphthalenes/chemistry , Tetrahydronaphthalenes/pharmacokinetics , Thiophenes/chemistry , Thiophenes/pharmacokinetics , Animals , Chemistry, Pharmaceutical , Delayed-Action Preparations , Male , Rats , Rats, Sprague-Dawley
10.
Bioorg Med Chem ; 23(14): 3925-32, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-25541202

ABSTRACT

The constitutive activity of the ghrelin receptor is of high physiological and pathophysiological relevance. In-depth structure-activity relationship studies revealed a palmitoylated ghrelin receptor ligand that displays an in vitro binding affinity in the low nanomolar range. Activity studies revealed inverse agonistic as well as antagonistic properties and in vitro metabolic analysis indicated a high stability in blood serum and liver homogenate. For metabolic testing in vivo, a combined approach of stable isotopic labeling and mass spectrometry-based analysis was established. Therefore, a heavy isotopic version of the peptide containing a (13)C-labeled palmitic acid was synthesized and a 1:1 ratio of a (12)C/(13)C-peptide mixture was injected into rats. Biological samples were analyzed by multiple reaction monitoring allowing simultaneous peptide detection and quantification. Measurements revealed a suitable bioavailability over 24h in rat serum and subsequent high-resolution mass spectrometry investigations showed only negligible degradation and slow body clearance. Hence, this method combination allowed the identification and evaluation of a highly potent and metabolically stable ghrelin receptor ligand in vivo.


Subject(s)
Drug Evaluation, Preclinical/methods , Mass Spectrometry/methods , Peptides/pharmacokinetics , Receptors, Ghrelin/metabolism , Animals , Biological Availability , COS Cells , Carbon Isotopes , Chlorocebus aethiops , Drug Stability , Humans , Ligands , Lipoylation , Male , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Peptides/blood , Peptides/chemistry , Rats, Inbred Lew , Receptors, Ghrelin/agonists , Structure-Activity Relationship
11.
PLoS One ; 9(7): e101426, 2014.
Article in English | MEDLINE | ID: mdl-24983633

ABSTRACT

Sutures can cause challenging surgical site infections, due to capillary effects resulting in bacteria permeating wounds. Anti-microbial sutures may avoid these complications by inhibiting bacterial pathogens. Recently, first triclosan-resistances were reported and therefore alternative substances are becoming clinically relevant. As triclosan alternative chlorhexidine, the "gold standard" in oral antiseptics was used. The aim of the study was to optimize novel slow release chlorhexidine coatings based on fatty acids in surgical sutures, to reach a high anti-microbial efficacy and simultaneously high biocompatibility. Sutures were coated with chlorhexidine laurate and chlorhexidine palmitate solutions leading to 11, 22 or 33 µg/cm drug concentration per length. Drug release profiles were determined in aqueous elutions. Antibacterial efficacy against Staphylococcus aureus was assessed in agar diffusion tests. Biocompatibility was evaluated via established cytotoxicity assay (WST-1). A commercially triclosan-containing suture (Vicryl Plus), was used as anti-microbial reference. All coated sutures fulfilled European Pharmacopoeia required tensile strength and proved continuous slow drug release over 96 hours without complete wash out of the coated drug. High anti-microbial efficacy for up to 5 days was observed. Regarding biocompatibility, sutures using 11 µg/cm drug content displayed acceptable cytotoxic levels according to ISO 10993-5. The highest potential for human application were shown by the 11 µg/cm chlorhexidine coated sutures with palmitic acid. These novel coated sutures might be alternatives to already established anti-microbial sutures such as Vicryl Plus in case of triclosan-resistance. Chlorhexidine is already an established oral antiseptic, safety and efficacy should be proven for clinical applications in anti-microbial sutures.


Subject(s)
Anti-Infective Agents, Local , Chlorhexidine , Coated Materials, Biocompatible , Enzyme Inhibitors , Palmitic Acid , Staphylococcus aureus/growth & development , Sutures , Anti-Infective Agents, Local/chemistry , Anti-Infective Agents, Local/pharmacokinetics , Anti-Infective Agents, Local/pharmacology , Chlorhexidine/chemistry , Chlorhexidine/pharmacokinetics , Chlorhexidine/pharmacology , Coated Materials, Biocompatible/chemistry , Coated Materials, Biocompatible/pharmacokinetics , Coated Materials, Biocompatible/pharmacology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/pharmacology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Palmitic Acid/pharmacology
12.
J Lipid Res ; 54(6): 1705-1711, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23511896

ABSTRACT

Diacylglycerols (DAG) are important lipid metabolites thought to induce muscle insulin resistance when present in excess; they can be synthesized de novo from plasma free fatty acids (FFA) or generated by hydrolysis of preexisting intracellular lipids. We present a new method to simultaneously measure intramyocellular concentrations of and the incorporation of [U-¹³C]palmitate from an intravenous infusion into individual DAG species. DAG were extracted from pulverized muscle samples using isopropanol:water:ethyl acetate (35:5:60; v:v:v). Chromatographic separation was conducted on reverse-phase column in binary gradient using 1.5 mM ammonium formate, 0.1% formic acid in water as solvent A, and 2 mM ammonium formate, 0.15% formic acid in methanol as solvent B. We used UPLC-ESI⁺-MS/MS in the multiple reaction monitoring (MRM) mode to separate the ions of interest from sample. Because DAG are a neutral lipid class, they were monitored as an ammonium adduct [M+NH4]⁺. To measure isotopic enrichment (for ¹³C16:0/16:0-DAG and ¹³C16:0/C18:1-DAG), we monitored the basic ions as [M+2+NH4]⁺ and the enriched compounds as [M+16+NH4]⁺. We were able to measure concentration and enrichment using 20 mg of skeletal muscle samples obtained from rats receiving a continuous infusion of [U-¹³C]palmitate. Applying this protocol to biological muscle samples proves that the method is sensitive, accurate, and efficient.


Subject(s)
Diglycerides/metabolism , Muscle, Skeletal/metabolism , Animals , Carbon Isotopes/pharmacokinetics , Carbon Isotopes/pharmacology , Chromatography, Liquid , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Isotope Labeling/methods , Male , Mass Spectrometry , Palmitic Acid/pharmacokinetics , Palmitic Acid/pharmacology , Rats , Rats, Wistar
13.
J Clin Endocrinol Metab ; 97(7): E1219-23, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22492868

ABSTRACT

CONTEXT: Increased adipose tissue lipolytic activity is considered an important factor in the pathogenesis of skeletal muscle insulin resistance associated with obesity. OBJECTIVE: The objective of the study was to evaluate the relationship between the rate of release of free fatty acids (FFA) into plasma and skeletal muscle insulin sensitivity in human subjects. METHODS: We determined the palmitate rate of appearance (Ra) per kilogram fat-free mass (an index of FFA availability to lean tissues) during basal conditions and during insulin infusion (to simulate postprandial insulin concentrations) and skeletal muscle insulin sensitivity, defined as the percent increase in the glucose rate of disappearance, in 110 nondiabetic women (body mass index 20.6-46.4 kg/m(2)) by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope tracer methods. RESULTS: Basal (r(s) = -0.379, P < 0.001) and insulin-suppressed (r(s) = -0.631, P < 0.001) palmitate Ra correlated negatively with skeletal muscle insulin sensitivity. However, the strength of the correlation was greater for palmitate Ra during insulin infusion than palmitate Ra during basal conditions (P = 0.0007) when lipolytic rates and FFA availability were reduced to less than 20% of basal values. The relative suppression of palmitate Ra correlated directly with the relative stimulation of glucose rate of disappearance during insulin infusion (r(s) = 0.530, P < 0.001). CONCLUSION: These data suggest that the correlation between FFA kinetics and muscle glucose metabolism is due to multiorgan insulin resistance rather than a direct effect of FFA itself on skeletal muscle insulin action and challenge the view that increased adipose tissue lipolytic rate is an important cause of insulin resistance.


Subject(s)
Adipose Tissue/metabolism , Insulin Resistance/physiology , Lipolysis/physiology , Muscle, Skeletal/metabolism , Obesity/metabolism , Adipose Tissue/drug effects , Adult , Aged , Diabetes Mellitus/metabolism , Fatty Acids, Nonesterified/administration & dosage , Fatty Acids, Nonesterified/pharmacokinetics , Fatty Acids, Nonesterified/pharmacology , Female , Glucose Clamp Technique , Humans , Insulin/administration & dosage , Insulin/pharmacology , Lipolysis/drug effects , Middle Aged , Muscle, Skeletal/drug effects , Obesity/complications , Palmitic Acid/administration & dosage , Palmitic Acid/pharmacokinetics , Radioactive Tracers , Young Adult
14.
Int J Pharm ; 424(1-2): 50-7, 2012 Mar 15.
Article in English | MEDLINE | ID: mdl-22226877

ABSTRACT

Albumin-binding achieved by fatty-acylation to drugs is considered to be an effective means of prolonging the circulation lifetimes of short-lived peptides. Here, exendin-4 was modified with palmitic acid, and the particle size and albumin-binding of palmitic acid-conjugated exendin-4 (Pal-Ex4) purified was investigated and visualized. Additionally, its pharmacokinetics and pharmacodynamics were evaluated in diabetic rodents. Pal-Ex4 had a greater molecular size (~125nm) and its albumin-binding was 5.6-fold that of Ex4. Molecular imaging showed that the subcutaneous absorption of Pal-Ex4 was delayed until 24h post-injection, whereas Ex4 was rapidly absorbed and distributed systemically. Pharmacokinetic and pharmacodynamic results confirmed these observations, for example, times to reach peak concentration and to achieve a blood glucose level nadir were greatly delayed versus Ex4, and the circulating half-life of Pal-Ex4 was much greater than that of Ex4. Consequently, the hypoglycemic degree of Pal-Ex4 (500 nmol/kg) was 4.2 fold greater than Ex4. Our results show that the extended hypoglycemic efficacy of Pal-Ex4 was due to (i) a delayed absorption due to micelle formation and (ii) an increased in vivo circulating half-life due to albumin-binding. We believe that this prototype of exendin-4 has considerable pharmaceutical potential as a systemic type 2 anti-diabetic treatment.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus/drug therapy , Hypoglycemic Agents/therapeutic use , Palmitic Acid/therapeutic use , Peptides/therapeutic use , Venoms/therapeutic use , Absorption , Animals , Blood Glucose/analysis , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/therapeutic use , Diabetes Mellitus/metabolism , Diabetes Mellitus, Experimental/metabolism , Exenatide , Fasting/metabolism , Half-Life , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacokinetics , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Micelles , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Particle Size , Peptides/chemistry , Peptides/pharmacokinetics , Serum Albumin/chemistry , Tissue Distribution , Venoms/chemistry , Venoms/pharmacokinetics
15.
Int J Nanomedicine ; 6: 547-55, 2011.
Article in English | MEDLINE | ID: mdl-21468357

ABSTRACT

The purpose of this study was to use solid lipid nanoparticles (SLN) to improve the pharmacological activity of ofloxacin. Ofloxacin-loaded SLN were prepared using palmitic acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier by a hot homogenization and ultrasonication method. The physicochemical characteristics of SLN were investigated by optical microscope, scanning electron microscopy, and photon correlation spectroscopy. Pharmacokinetics was studied after oral administration in mice. In vitro antibacterial activity and in vivo antibacterial efficacy of the SLN were investigated using minimal inhibitory concentrations (MIC) and a mouse protection model. The results demonstrated that the encapsulation efficiency, loading capacity, diameter, polydispersivity index, and zeta potential of the nanoparticles were 41.36% ± 1.50%, 4.40% ± 0.16%, 156.33 ± 7.51 nm, 0.26 ± 0.04, and -22.70 ± 1.40 mv, respectively. The SLN showed sustained release and enhanced antibacterial activity in vitro. Pharmacokinetic results demonstrated that SLN increased the bioavailability of ofloxacin by 2.27-fold, and extended the mean residence time of the drug from 10.50 to 43.44 hours. Single oral administrations of ofloxacin-loaded nanoparticles at 3 drug doses, 5 mg/kg, 10 mg/kg, and 20 mg/kg, all produced higher survival rates of lethal infected mice compared with native ofloxacin. These results indicate that SLN might be a promising delivery system to enhance the pharmacological activity of ofloxacin.


Subject(s)
Anti-Bacterial Agents , Fluoroquinolones , Nanoparticles/chemistry , Ofloxacin , Palmitic Acid , Administration, Oral , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Biological Availability , Emulsions/chemistry , Fluoroquinolones/chemistry , Fluoroquinolones/pharmacokinetics , Male , Mice , Microscopy, Electron, Scanning , Ofloxacin/chemistry , Ofloxacin/pharmacokinetics , Palmitic Acid/chemistry , Palmitic Acid/pharmacokinetics , Particle Size , Polyvinyl Alcohol/chemistry , Staphylococcus aureus/pathogenicity , Surface Properties
16.
Am J Physiol Endocrinol Metab ; 300(4): E746-51, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21304064

ABSTRACT

We hypothesized that individuals who have undergone gastric bypass have greater insulin sensitivity that obese subjects but less compared with lean. We measured free fatty acid (FFA) and glucose kinetics during a two-step, hyperinsulinemic euglycemic clamp in nondiabetic subjects who were 38 ± 5 mo post-gastric bypass surgery (GB; n = 15), in lean subjects (L; n = 15), and in obese subjects (O; n = 16). Fasting FFAa were not significantly different between the three study groups but during both doses of insulin were significantly higher in O than in either GB or L. The effective insulin concentration resulting in half-maximal suppression of FFA was similar in L and GB and significantly less in both groups compared with O. Glucose infusion rates during low-dose insulin were not significantly different in GB compared with either L or O. During high-dose insulin, glucose infusion rates were significantly greater in GB than in O but less than in L. Endogenous glucose production in GB was significantly lower than O only during low dose of insulin. We conclude that gastric bypass is associated with improvements in adipose tissue insulin sensitivity to levels similar to lean, healthy persons and also with improvements in the response of glucose metabolism to insulin. These changes may be due to preferential reduction in visceral fat and decreased FFA availability. However, some differences in insulin sensitivity in GB remain compared with L. Residual insulin resistance may be related to excess total body fat or abnormal lipolysis and requires further study.


Subject(s)
Gastric Bypass , Insulin/pharmacology , Lipolysis/drug effects , Adult , Blood Glucose/metabolism , Case-Control Studies , Cross-Sectional Studies , Down-Regulation/drug effects , Fatty Acids, Nonesterified/analysis , Fatty Acids, Nonesterified/blood , Female , Gastric Bypass/rehabilitation , Gastric Bypass/statistics & numerical data , Glucose Tolerance Test , Health , Humans , Insulin/metabolism , Insulin Resistance/physiology , Male , Obesity/blood , Obesity/metabolism , Obesity/surgery , Palmitic Acid/pharmacokinetics
17.
Metabolism ; 58(9): 1248-55, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19500809

ABSTRACT

Free fatty acid (FFA) availability increases several-fold during exercise and remains significantly elevated for at least 3 to 6 hours after exercise cessation. Little, however, is known regarding the duration of the postexercise rise in FFA flux. In the present study, we used stable isotope-labeled palmitate infusion to examine fatty acid metabolism in 27 healthy untrained men and women (age, 29 +/- 7 years; body mass index, 25 +/- 4 kg/m2) between 13 to 16 hours and 21 to 24 hours after a single bout of moderate-intensity endurance exercise (1-2 hours at 60% of peak oxygen consumption), performed in the evening, and after a time-matched resting trial. Postabsorptive FFA rate of appearance (Ra) and FFA concentration in plasma were significantly greater after exercise than rest throughout the recovery period (P < .015), but the exercise-induced increases declined from approximately 40% at 13 to 16 hours to approximately 10% at 21 to 24 hours postexercise (P = .001). The magnitude of the exercise-induced increase in plasma FFA concentration was proportional to the increase in FFA Ra. Correlation analysis demonstrated that exercise-induced changes in plasma FFA Ra at 13 to 16 hours are (1) negatively associated with resting plasma FFA Ra and (2) positively associated with the net energy expenditure of exercise and the exercise-induced changes in whole-body fat oxidation rate (all P values < .05). In multivariate stepwise linear regression analysis, baseline plasma FFA Ra (P < or = .008) and net energy expenditure of exercise (P < or = .005) independently predicted the exercise-induced change in plasma FFA Ra at 13 to 16 hours. We conclude that the exercise-induced increase in FFA mobilization is (1) long-lived, persisting for 12 to 24 hours after exercise, with a progressive decline with time; (2) greater in subjects with low than high resting plasma FFA availability; and (3) greater after exercise with high than low energy demand.


Subject(s)
Basal Metabolism/physiology , Energy Metabolism/physiology , Exercise/physiology , Fatty Acids, Nonesterified/metabolism , Recovery of Function/physiology , Adipose Tissue/metabolism , Adult , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/pharmacokinetics , Female , Heart Rate/physiology , Humans , Insulin/blood , Kinetics , Male , Oxidation-Reduction , Palmitic Acid/administration & dosage , Palmitic Acid/pharmacokinetics , Rest/physiology , Young Adult
18.
J Nucl Cardiol ; 16(3): 411-21, 2009.
Article in English | MEDLINE | ID: mdl-19212800

ABSTRACT

BACKGROUND: The goal of this study was to test whether myocardial triglyceride (TG) turnover including oxidation of TG-derived fatty acids (FA) could be assessed with PET and (11)C-palmitate. METHODS AND RESULTS: A total of 26 dogs were studied fasted (FAST), during Intralipid infusion (IL), during a hyperinsulinemic-euglycemic clamp without (HIEG), or with Intralipid infusion (HIEG + IL). (11)C-palmitate was injected, and 45 minutes were allowed for labeling of myocardial TG pool. 3D PET data were then acquired for 60 minutes, with first 15 minutes at baseline followed by 45 minutes during cardiac work stimulated with constant infusion of either phenylephrine (FAST, n = 6; IL, n = 6; HIEG + IL, n = 6) or dobutamine (FAST, n = 4; HIEG, n = 4). Myocardial (11)C washout during adrenergic stimulation (AS) was fitted to a mono-exponential function (Km(PET)). To determine the source of this (11)C clearance, Km(PET) was compared to direct coronary sinus-arterial measurements of total (11)C activity, (11)C-palmitate, and (11)CO(2). Before AS, PET curves in all groups were flat indicating absence of net clearance of (11)C activity from heart. In both FAST groups, AS resulted in negligible net (11)C activity and (11)CO(2) production higher than net (11)C-palmitate uptake. AS with phenylephrine resulted in net myocardial uptake of total (11)C activity and (11)C-palmitate in IL and HIEG + IL, and (11)CO(2) production lower than (11)C-palmitate uptake. In contrast, AS with dobutamine in HIEG resulted in net clearance of all (11)C metabolites (total (11)C activity, (11)C-palmitate and (11)CO(2)) with (11)CO(2) contributing 66% to endogenous FA oxidation. The AS resulted in significant Km(PET) in all the groups, except HIEG + IL. However, positive correlation between Km(PET) and (11)CO(2) was observed only in HIEG (R (2) = 0.83, P = .09). CONCLUSIONS: This is the first study to demonstrate that using PET and pre-labeling of intracardiac TG pool with (11)C-palmitate, noninvasive assessment of myocardial TG use is feasible under metabolic conditions that favor endogenous TG use such as increased metabolic demand (beta-adrenergic stimulation of cardiac work) with limited availability of exogenous substrate (HIEG).


Subject(s)
Heart/diagnostic imaging , Myocardium/metabolism , Palmitic Acid/pharmacokinetics , Positron-Emission Tomography/methods , Triglycerides/metabolism , Animals , Carbon Radioisotopes/pharmacokinetics , Dogs , Male , Metabolic Clearance Rate , Oxidation-Reduction , Radiopharmaceuticals/pharmacokinetics
19.
J Comp Physiol B ; 179(3): 325-33, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19005657

ABSTRACT

Seahorses, sea dragons and pipefishes of the teleost family Syngnathidae are unique in that embryos develop within specialized brooding structures of the male. We enriched brooding Syngnathus fuscus and Syngnathus floridae males with injections of L-lysine-[(15)N(2)] and 16:0-palmitic acid 1-[(13)C] to demonstrate embryonic uptake of paternally-derived nutrients. While all embryos demonstrated amino acid enrichment, late stages showed significantly higher [(15)N], indicating greater utilization of paternal resources as yolk reserves diminished and embryonic energy demands increased. Limited embryonic [(13)C] uptake, defined as less than 10% of adult enrichment, in 75 and 81% of S. floridae and S. fuscus respectively signified rapid lipid metabolism and thus the need for greater enrichment. Interspecific differences in embryonic uptake of paternally-derived nutrients were not demonstrated. However, interspecific differences in egg nutrient reserves and fry size but comparable fry nutrient levels along with data from a published paternal exposure study indicate paternal transfer in S. fuscus most likely compensates for the comparative egg nutrient deficiency. This study is the first to our knowledge to provide direct evidence for the functional significance of the brood pouch in nutrient provisioning. These results add comparative information on the diversity of Syngnathid paternal care and further our understanding of paternal influence on development.


Subject(s)
Animal Nutritional Physiological Phenomena/physiology , Paternal Behavior , Smegmamorpha/embryology , Animals , Carbon Isotopes/pharmacokinetics , Chromatography, Gas , Embryo, Nonmammalian/metabolism , Lysine/pharmacokinetics , Male , Nitrogen Isotopes/pharmacokinetics , Palmitic Acid/pharmacokinetics , Smegmamorpha/metabolism , Virginia
20.
Am J Physiol Endocrinol Metab ; 294(4): E645-53, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18212023

ABSTRACT

When using (13)C tracer to measure plasma fat oxidation, an acetate recovery factor should be determined in every subject to correct for label sequestration. Less is known regarding the acetate recovery factor for dietary fatty acid oxidation. We compiled data from six studies to investigate the determinants of the dietary acetate recovery factor (dARF) at rest and after physical activity interventions and compared the effects of different methods of dARF calculation on both the fat oxidation and its variability. In healthy lean subjects, dARF was 50.6 +/- 5.4% dose (n = 56) with an interindividual coefficient of variation of 10.6% at rest and 9.2% after physical activity modifications. The physical activity interventions did not impact dARF, and the intraindividual coefficient of variation was 4.6%. No major anthropological or physiological determinants were detected except for resting metabolic rate, which explains 7.4% of the dARF variability. Applying an individual or an average group dARF did not affect the mean and the variability of the derived dietary lipid oxidation at rest or after physical activity interventions. Using a mean dARF for a group leads to over- or underestimation of fat oxidation of less than 10% in individual subjects. Moreover, the use of a group or individual correction did not affect the significant relationship found between fasting respiratory exchange ratio and dietary fat oxidation. These data indicate that an average dARF can be applied for longitudinal and cross-sectional studies investigating dietary lipid metabolism.


Subject(s)
Acetates/pharmacokinetics , Carbon Isotopes , Dietary Fats/pharmacokinetics , Physical Exertion/physiology , Rest/physiology , Adult , Breath Tests , Female , Humans , Kinetics , Male , Mass Spectrometry , Oleic Acid/pharmacokinetics , Oxidation-Reduction , Palmitic Acid/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...